Fosaprepitant Dosing Frequency
Fosaprepitant is administered as a single 150 mg IV dose on Day 1 only for both highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) in adults, with no repeat dosing on subsequent days. 1
Standard Adult Dosing Regimen
For HEC (e.g., cisplatin-based regimens):
- Day 1: Fosaprepitant 150 mg IV over 20-30 minutes, approximately 30 minutes before chemotherapy
- Days 2-4: No fosaprepitant (only continue dexamethasone 8 mg orally or IV)
- The single dose provides NK-1 receptor blockade for the entire 5-day risk period 2, 1
For MEC (e.g., carboplatin, oxaliplatin):
- Day 1: Fosaprepitant 150 mg IV over 20-30 minutes, approximately 30 minutes before chemotherapy
- Days 2-3: No fosaprepitant needed
- Single-dose administration is sufficient 2, 1
Pediatric Dosing Frequency
For children 6 months to 17 years receiving single-day chemotherapy regimens:
Single-dose regimen (preferred):
- Ages 12-17 years: 150 mg IV on Day 1 only
- Ages 2 to <12 years: 4 mg/kg IV (max 150 mg) on Day 1 only
- Ages 6 months to <2 years: 5 mg/kg IV (max 150 mg) on Day 1 only 1
3-day regimen (alternative for multi-day chemotherapy):
- Ages 12-17 years: 115 mg IV Day 1, then oral aprepitant 80 mg Days 2-3
- Ages 6 months to <12 years: 3 mg/kg IV Day 1 (max 115 mg), then oral aprepitant 2 mg/kg Days 2-3 (max 80 mg) 1, 3
Key Clinical Considerations
Why single-dose works: The 150 mg IV dose maintains >90% NK-1 receptor occupancy in the CNS for at least 48 hours, providing adequate coverage for both acute (0-24h) and delayed (25-120h) CINV phases 4. Clinical trials demonstrated non-inferiority to the 3-day oral aprepitant regimen (125 mg/80 mg/80 mg) 1.
Repeat dosing intervals:
- Fosaprepitant can be safely repeated with each chemotherapy cycle (typically every 2-3 weeks) 5, 6
- For concurrent chemoradiotherapy, weekly dosing has been studied but is not standard practice 7
- Do NOT administer more frequently than once per chemotherapy cycle
Hepatic impairment: No dose adjustment is required for fosaprepitant in hepatic impairment, as the FDA label does not specify modifications 1. This differs from some other agents where hepatic metabolism is a concern.
Common Pitfalls to Avoid
- Do not confuse with oral aprepitant dosing: Oral aprepitant requires 3 days (125/80/80 mg), but IV fosaprepitant is a single 150 mg dose
- Do not repeat daily: Unlike 5-HT3 antagonists that may require multi-day dosing, fosaprepitant's long half-life makes daily administration unnecessary and potentially wasteful
- Adjust dexamethasone, not fosaprepitant: Reduce dexamethasone dose by 50% on Days 1-2 when using fosaprepitant due to CYP3A4 inhibition (12 mg instead of 20 mg) 2, 1
- Infusion site reactions: More common with fosaprepitant than oral aprepitant; infuse over the full 20-30 minutes to minimize risk 4
The single-dose regimen offers superior convenience and adherence compared to multi-day oral regimens while maintaining equivalent antiemetic efficacy 2, 8, 1.